SCHEMBL1932191

SCHEMBL1932191

O=C(O)CCCSc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 1.00
HDAC3 O15379 3/20 0.59
HDAC4 P56524 3/20 0.59
HDAC1 Q13547 3/20 0.59
HDAC7 Q8WUI4 3/20 0.59
HDAC2 Q92769 3/20 0.59
HDAC10 Q969S8 3/20 0.59
HDAC11 Q96DB2 3/20 0.59
HDAC8 Q9BY41 3/20 0.59
HDAC6 Q9UBN7 3/20 0.59
HDAC9 Q9UKV0 3/20 0.59
HDAC5 Q9UQL6 3/20 0.59
FFAR1 O14842 1/20 0.57
MAPK1 P28482 2/20 0.56
CYP1A2 P05177 2/20 0.55
CYP2D6 P10635 2/20 0.55
CYP2C19 P33261 2/20 0.55
CYP3A4 P08684 1/20 0.55
LMNA P02545 2/20 0.53
RAB9A P51151 5/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2351099 0.94 ALDH1A1 (0.89) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL8088391 0.92 ALDH1A1 (0.85) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL5081086 0.92 ALDH1A1 (0.85) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL7820281 0.92 ALDH1A1 (0.85) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL3943933 0.92 ALDH1A1 (0.85) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL710248 0.92 ALDH1A1 (0.85) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL1930794 0.87 ALDH1A1 (0.77) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL3959624 0.86 ALDH1A1 (0.75) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL9463394 0.85 ALDH1A1 (0.73) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL8160357 0.84 ALDH1A1 (0.72) ALDH1A1HDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12544350-B2 Combinatorial antitumor treatment methods and related compositions, kits, and systems KLOTHO THERAPEUTICS, INC. (US) 2026-02-10 US claimed
US-20240277650-A1 NOVEL COMBINATORIAL ANTITUMOR TREATMENT METHODS AND RELATED COMPOSITIONS, KITS, AND SYSTEMS KLOTHO THERAPEUTICS, INC. 2024-08-22 US claimed
US-20240216514-A1 NOVEL ANTITUMOR COMPOUNDS AND RELATED METHODS OF MANUFACTURE AND USE KLOTHO THERAPEUTICS, INC. 2024-07-04 US claimed
EP-4366716-A1 NOVEL COMBINATORIAL ANTITUMOR TREATMENT METHODS AND RELATED COMPOSITIONS, KITS, AND SYSTEMS Klotho Therapeutics, Inc. (US) 2024-05-15 EP claimed
US-20230278953-A1 WATER SOLUBLE PRODRUGS OF PTBA FOR USE IN HDAC INHIBITION AND ENHANCING RENAL RECOVERY FOLLOWING ACUTE KIDNEY INJURY KLOTHO THERAPEUTICS, INC. 2023-09-07 US claimed
EP-4178560-A1 WATER SOLUBLE PRODRUGS OF PTBA FOR USE IN HDAC INHIBITION AND ENHANCING RENAL RECOVERY FOLLOWING ACUTE KIDNEY INJURY Klotho Therapeutics, Inc. (US) 2023-05-17 EP claimed
WO-2023283648-A1 NOVEL COMBINATORIAL ANTITUMOR TREATMENT METHODS AND RELATED COMPOSITIONS, KITS, AND SYSTEMS KLOTHO THERAPEUTICS, INC. (US) 2023-01-12 WO claimed
WO-2022217255-A1 NOVEL ANTITUMOR COMPOUNDS AND RELATED METHODS OF MANUFACTURE AND USE KLOTHO THERAPEUTICS, INC. (US) 2022-10-13 WO claimed
WO-2022011174-A1 WATER SOLUBLE PRODRUGS OF PTBA FOR USE IN HDAC INHIBITION AND ENHANCING RENAL RECOVERY FOLLOWING ACUTE KIDNEY INJURY KLOTHO THERAPEUTICS, INC. (US) 2022-01-13 WO claimed
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury UNIVERSITY OF PITTSBURGH - OF T 2020-07-02 US claimed
EP-1799638-B1 PROCESS FOR PREPARING AROMATIC THIOPHENYL KETONES CIBA HOLDING INC (CH) 2008-07-30 EP claimed
EP-1799638-A1 PROCESS FOR PREPARING AROMATIC THIOPHENYL KETONES CIBA SPECIALTY CHEMICALS HOLDING INC. Patent Departement (CH) 2007-06-27 EP claimed
US-7045321-B2 POLYHYDROXYALKANOATE CONTAINING UNIT WITH PHENYLSULFANYL STRUCTURE IN THE SIDE CHAIN, PROCESS FOR ITS PRODUCTION, CHARGE CONTROL AGENT, TONER BINDER AND TONER WHICH CONTAIN NOVEL POLYHYDROXYALKANOATE, AND IMAGE-FORMING METHOD AND IMAGE-FORMING APPARATUS WHICH MAKE USE OF THE TONER CANON KABUSHIKI KAISHA (JP) 2006-05-16 US claimed
WO-2006034966-A1 PROCESS FOR PREPARING AROMATIC THIOPHENYL KETONES CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2006-04-06 WO claimed
US-20030013841-A1 Novel polyhydroxyalkanoate containing unit with phenylsulfanyl structure in the side chain, process for its production, charge control agent, toner binder and toner which contain novel polyhydroxyalkanoate, and image-forming method and image-forming apparatus which make use of the toner CANON KABUSHIKI KAISHA (JP) 2003-01-16 US claimed
EP-1236755-A2 Novel polyhydroxyalkanoate containing unit phenylsulfanyl structure in the side cahin, process for its production, charge control agent, toner binder and toner which contain novel polyhydroxyalkanoate, and imageforming apparatus which make use of the toner CANON KABUSHIKI KAISHA (JP) 2002-09-04 EP claimed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP claimed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO claimed
EP-0505467-A1 PHARMACOLOGICALLY ACTIVE AMIDE CARBOXYLATE DERIVATIVES Astra Pharmaceuticals Limited (GB) 1992-09-30 EP claimed
WO-1991008737-A2 PHARMACOLOGICALLY ACTIVE AMIDE CARBOXYLATE DERIVATIVES FISONS PLC (GB) 1991-06-27 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278953-A1 WATER SOLUBLE PRODRUGS OF PTBA FOR USE IN HDAC INHIBITION AND ENHANCING RENAL RECOVERY FOLLOWING ACUTE KIDNEY INJURY HDAC1, HDAC9, HDAC7 ALDH1A1 111/4885HDAC3 4/4885HDAC4 8/4885
US-12544350-B2 Combinatorial antitumor treatment methods and related compositions, kits, and systems TPMT, BCL2A1, XPA ALDH1A1 615/4885HDAC3 4052/4885HDAC4 4442/4885
US-20240277650-A1 NOVEL COMBINATORIAL ANTITUMOR TREATMENT METHODS AND RELATED COMPOSITIONS, KITS, AND SYSTEMS PTBP3, PTBP1, TYMS ALDH1A1 504/4885HDAC3 1652/4885HDAC4 2228/4885
US-20240216514-A1 NOVEL ANTITUMOR COMPOUNDS AND RELATED METHODS OF MANUFACTURE AND USE BID, TBCA, PTBP3 ALDH1A1 168/4885HDAC3 553/4885HDAC4 673/4885
US-20200207691-A1 Class of HDAC Inhibitors Expands the Renal Progenitor Cells Population and Improves the Rate of Recovery from Acute Kidney Injury HDAC1, HDAC9, HDAC11 ALDH1A1 351/4885HDAC3 9/4885HDAC4 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.